Outcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factors
Outcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factors
The introduction of nucleot(s)ide analogues (NAs) for oral antiviral therapy has dramatically improved the clinical outcome of patients with chronic hepatitis B. NAs appear to be safe and induce potent suppression of viral replication. However, they are associated with a low rate of HBsAg seroclearance, the gold standard of successful treatment, and also with a relatively high rate of virological relapse after discontinuation. As a result, long-term treatment is needed. The optimal duration of NA treatment currently remains unclear, nevertheless in some patients NA treatment can be stopped with a relatively low probability of relapse. Whether NAs are able to induce a sustained off-treatment response is an important area for research. This article reviews the relapse rate after cessation of treatment with NAs in chronic hepatitis B patients with the goal of identifying possible predictive factors of relapse.
173-181
Kranidioti, H.
67c560b5-240b-4445-88fd-69bee09e1570
Manolakopoulos, S.
6142cc46-9179-44ed-a562-46e19357a97a
Khakoo, S.I.
6c16d2f5-ae80-4d9b-9100-6bfb34ad0273
28 June 2015
Kranidioti, H.
67c560b5-240b-4445-88fd-69bee09e1570
Manolakopoulos, S.
6142cc46-9179-44ed-a562-46e19357a97a
Khakoo, S.I.
6c16d2f5-ae80-4d9b-9100-6bfb34ad0273
Kranidioti, H., Manolakopoulos, S. and Khakoo, S.I.
(2015)
Outcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factors.
Annals of Gastroenterology, 28 (2), .
(PMID:25831071)
Abstract
The introduction of nucleot(s)ide analogues (NAs) for oral antiviral therapy has dramatically improved the clinical outcome of patients with chronic hepatitis B. NAs appear to be safe and induce potent suppression of viral replication. However, they are associated with a low rate of HBsAg seroclearance, the gold standard of successful treatment, and also with a relatively high rate of virological relapse after discontinuation. As a result, long-term treatment is needed. The optimal duration of NA treatment currently remains unclear, nevertheless in some patients NA treatment can be stopped with a relatively low probability of relapse. Whether NAs are able to induce a sustained off-treatment response is an important area for research. This article reviews the relapse rate after cessation of treatment with NAs in chronic hepatitis B patients with the goal of identifying possible predictive factors of relapse.
This record has no associated files available for download.
More information
Accepted/In Press date: 7 November 2014
Published date: 28 June 2015
Organisations:
Clinical & Experimental Sciences
Identifiers
Local EPrints ID: 390065
URI: http://eprints.soton.ac.uk/id/eprint/390065
ISSN: 1108-7471
PURE UUID: c6dc5512-f8b7-48e3-a424-3e7c629b2cc1
Catalogue record
Date deposited: 17 Mar 2016 16:21
Last modified: 10 May 2023 01:37
Export record
Contributors
Author:
H. Kranidioti
Author:
S. Manolakopoulos
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
